STCube Inc (052020) - Total Liabilities
Based on the latest financial reports, STCube Inc (052020) has total liabilities worth ₩18.02 Billion KRW (≈ $12.21 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
STCube Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how STCube Inc's total liabilities have evolved over time, based on quarterly financial data. See STCube Inc short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
STCube Inc Competitors by Total Liabilities
The table below lists competitors of STCube Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kore Potash Plc
AU:KP2
|
Australia | AU$453.96K |
|
Sang-A Frontec Co.Ltd
KQ:089980
|
Korea | ₩171.13 Billion |
|
QuantumSi Inc
NASDAQ:QSI
|
USA | $12.60 Million |
|
SR Accord
TA:SRAC
|
Israel | ILA1.32 Billion |
|
UniTest Incorporation
KQ:086390
|
Korea | ₩79.12 Billion |
|
Atomera Inc
NASDAQ:ATOM
|
USA | $2.71 Million |
|
Plum Acquisition Corp. IV Class A Ordinary Shares
NASDAQ:PLMK
|
USA | $7.36 Million |
|
Goknur Gida Maddeleri Enerji Imalati Ithalat Ihracat Ticaret ve Sanayi A.S.
IS:GOKNR
|
Turkey | TL3.67 Billion |
Liability Composition Analysis (2009–2025)
This chart breaks down STCube Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 052020 market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how STCube Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for STCube Inc (2009–2025)
The table below shows the annual total liabilities of STCube Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩18.11 Billion ≈ $12.27 Million |
+2.74% |
| 2024-12-31 | ₩17.63 Billion ≈ $11.95 Million |
+65.54% |
| 2023-12-31 | ₩10.65 Billion ≈ $7.22 Million |
+8.11% |
| 2022-12-31 | ₩9.85 Billion ≈ $6.68 Million |
+1.58% |
| 2021-12-31 | ₩9.70 Billion ≈ $6.57 Million |
-32.79% |
| 2020-12-31 | ₩14.43 Billion ≈ $9.78 Million |
-38.77% |
| 2019-12-31 | ₩23.56 Billion ≈ $15.97 Million |
+18.32% |
| 2018-12-31 | ₩19.91 Billion ≈ $13.50 Million |
+171.44% |
| 2017-12-31 | ₩7.34 Billion ≈ $4.97 Million |
-36.40% |
| 2016-12-31 | ₩11.54 Billion ≈ $7.82 Million |
+370.34% |
| 2015-12-31 | ₩2.45 Billion ≈ $1.66 Million |
-74.73% |
| 2014-12-31 | ₩9.70 Billion ≈ $6.58 Million |
-41.65% |
| 2013-12-31 | ₩16.63 Billion ≈ $11.27 Million |
+237.74% |
| 2012-12-31 | ₩4.92 Billion ≈ $3.34 Million |
-9.52% |
| 2011-12-31 | ₩5.44 Billion ≈ $3.69 Million |
+35.83% |
| 2010-12-31 | ₩4.01 Billion ≈ $2.72 Million |
+19.03% |
| 2009-12-31 | ₩3.37 Billion ≈ $2.28 Million |
-- |
About STCube Inc
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a tech… Read more